The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Try the newly designed Company Pages!
Switch now

Biogen IDEC

  • BIIB
  • NASDAQ
  • Consumer Products
  • Latest 336.39
  • Currency US$
  • Change 0.0000
  • Percent Change 0.00 %
  • Volume 650
  • Mon Jul 28, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 0.0000
  • Previous Close 336.39
  • High 0.0000
  • Low 0.0000
  • Bidx1 334.51
  • Askx2 340.00
  • 52-week High03/19 358.89
  • 52-week Low08/21 203.55
  • Beta 1.199
  • Market Cap 79,791.71M
  • EPS 9.00
  • P/E 37.377
  • Forward P/E
  • PEG
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $8,344,830,000
  • Earnings $2,139,400,000
  • Return on Equity 22.87%

Cash Flow

  • Cash Flow --
  • Cash $863,190,000
  • Current Ratio 2.05

12 months ended Jun 30, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $12,918,000,000
  • Liabilities $3,352,770,000
  • Liabilities-to-Equity Ratio 0.35

Price Ratios

  • Price to Sales 9.56
  • Price to Book 8.34
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Jul 23 $2.80 Oct 27 $3.53
Surprises Jul 23 24.64% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Jul 29, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

IDEC Pharmaceuticals Corporation is a biopharmaceutical company engaged primarily in the research, development and commercialization of targeted therapies for the treatment of cancer and autoimmune and inflammatory diseases. Their first commercial product, Rituxan, and our most advanced product candidate, ZEVALIN, are for use in the treatment of certain B-cell non-Hodgkin's lymphomas. They are also developing products for the treatment of various autoimmune diseases (such as psoriasis, rheumatoid arthritis and lupus).

Related Securities
Symbol Type Latest % Chg

Officers

  • William D. Young Chairman of the Board of Direc
  • George A. Scangos Chief Executive Officer
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

225 BINNEY STREET
CAMBRIDGE, MA
02142

Phone: (781)-464-2000
Fax: (617)-6792617


www.biogenidec.com

Ideas & Discussion

Live Discussion of BIIB on StockTwits
The Globe and Mail has
updated our Company Pages
Switch to the newly designed Company Pages format today for a more in-depth look at the companies you're following and pages that are easier to navigate. If you prefer the old layout after trying the new Company Pages, you can switch back anytime.